Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

被引：0
|
作者：
Ghadeer K. Dawwas
Steven M. Smith
Haesuk Park
机构：
[1] University of Florida,Department of Pharmaceutical Outcomes and Policy, College of Pharmacy
[2] University of Florida,Department of Pharmacotherapy and Translational Research, College of Pharmacy
[3] University of Florida,Department of Community Health and Family Medicine, College of Medicine
来源：
Cardiovascular Diabetology | / 17卷
关键词：
Type 2 diabetes; DPP-4 inhibitors; GLP-1 agonists; Safety; Heart failure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
    Dawwas, Ghadeer K.
    Smith, Steven M.
    Park, Haesuk
    CARDIOVASCULAR DIABETOLOGY, 2018, 17
  • [2] Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization
    Lyu, Beini
    Grams, Morgan E.
    Chang, Alex
    Inker, Lesley A.
    Coresh, Josef
    Shin, Jung-Im
    AMERICAN JOURNAL OF CARDIOLOGY, 2022, 165 : 124 - 130
  • [3] Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
    Nauck, Michael A.
    Meier, Juris J.
    Cavender, Matthew A.
    Abd El Aziz, Mirna
    Drucker, Daniel J.
    CIRCULATION, 2017, 136 (09) : 849 - U176
  • [4] Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists
    Wang, Yufan
    Zhao, Li
    Huang, Qianfang
    Peng, Yongde
    JOURNAL OF DIABETES, 2014, 6 (02) : 164 - 166
  • [5] Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist
    Kershaw V. Patel
    Ashish Sarraju
    Ian J. Neeland
    Darren K. McGuire
    Current Cardiology Reports, 2020, 22
  • [6] Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist
    Patel, Kershaw, V
    Sarraju, Ashish
    Neeland, Ian J.
    McGuire, Darren K.
    CURRENT CARDIOLOGY REPORTS, 2020, 22 (10)
  • [7] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    Drucker, Daniel J.
    Nauck, Michael A.
    LANCET, 2006, 368 (9548): : 1696 - 1705
  • [8] Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study
    Santos-Pardo, Irene
    Lagerqvist, Bo
    Ritsinger, Viveca
    Witt, Nils
    Norhammar, Anna
    Nystrom, Thomas
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 330 : 23 - 29
  • [9] Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors
    Phyo T. Htoo
    John B. Buse
    Mugdha Gokhale
    M. Alison Marquis
    Virginia Pate
    Til Stürmer
    European Journal of Clinical Pharmacology, 2016, 72 : 1013 - 1023
  • [10] Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors
    Htoo, Phyo T.
    Buse, John B.
    Gokhale, Mugdha
    Marquis, M. Alison
    Pate, Virginia
    Sturmer, Til
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (08) : 1013 - 1023
12345